What is the Purpose of this Study?
To evaluate the safety and tolerability of BIIB122 in participants with LRRK2-PD during the double-blind period
Eligibility
- * For heterozygous pathogenic LRRK2 mutation carriers: ≥ 30 to ≤ 80 years
- * For homozygous pathogenic LRRK2 mutation carriers: ≥ 30 years
- * Have screening genetic test results verifying the presence of a pathogenic LRRK2 variant.
- * Have a clinical diagnosis of PD meeting the Movement Disorder Society Clinical Diagnostic Criteria.
Where can I participate?
Beverly
More about this Clinical Trial
What is the full name of this clinical trial?
A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease